A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer
International Journal of Clinical Oncology, 05/07/2012
Shitara K et al. – Although the retrospective nature of this study and the small number of patients is a major limitation, S–1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) were associated with similar efficacy and safety in patients with advanced gastric cancer (AGC).
The authors retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC.
From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period.
The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p=0.62).
There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p=0.91) and overall survival (median 13.8 vs. 13.5months; p=0.97) between the SP and XP groups.
The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups.
Although grade 1 or 2 hand–foot syndrome was more common in the XP group, no patients experienced grade 3 or more.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.